RUNX1 and chronic myelogenous leukemia, BCR-ABL1 positive: Although somewhat paradoxically, experimental expression of wt., but not mutant, AML1 protects BCR-ABL-transformed cells from imatinib-induced apoptosis, indicating the role of up-regulated wt.AML1 in imatinib resistance and disease progression of CML [27].